|1.||Old, Lloyd J: 157 articles (10/2015 - 02/2002)|
|2.||Rosenberg, Steven A: 106 articles (01/2016 - 01/2002)|
|3.||Ferrone, Soldano: 84 articles (10/2015 - 05/2003)|
|4.||Gnjatic, Sacha: 82 articles (03/2015 - 08/2002)|
|5.||Ritter, Gerd: 79 articles (10/2015 - 04/2002)|
|6.||Romero, Pedro: 71 articles (11/2014 - 02/2002)|
|7.||Jungbluth, Achim A: 71 articles (06/2014 - 02/2002)|
|8.||Hill, Adrian V S: 64 articles (12/2015 - 03/2002)|
|9.||Restifo, Nicholas P: 63 articles (03/2015 - 06/2002)|
|10.||Wu, T-C: 62 articles (07/2015 - 03/2002)|
08/03/2010 - "Active immunization using tumor antigen-loaded dendritic cells holds promise for the adjuvant treatment of cancer to eradicate or control residual disease, but so far, most dendritic cell trials have been performed in end-stage cancer patients with high tumor loads. "
02/01/1987 - "In our own studies two types of approaches were also effective with the highly metastatic mouse tumor line ESb which carries a weak tumor associated antigen. "
01/01/2015 - "However, high-avidity TCRs are not always available, particularly among self/tumor antigen-specific T cells, most of which are eliminated by central and peripheral deletion mechanisms. "
01/01/2014 - "In this way, through the use of adjuvants, immune responses can be highly customizable and functionally tailored for optimal efficacy against pathogen specific (i.e., infectious agent) or non-pathogen (i.e., cancer) antigens. "
12/01/2013 - "Although immunization with each individual antigen was partially effective in inhibiting tumor growth, immunization with the multiantigen vaccine was highly effective, blocking development of palpable lesions in 65% of mice and slowing tumor growth in the infrequent palpable tumors, which did arise. "
04/01/2009 - "In this study, we evaluated the protective efficacy of immunizing mice with caseinolytic protease (ClpP) protein antigen whose gene sequences were shown to be highly conserved in different strains of Streptococcus pneumoniae in an invasive-disease model (intraperitoneal infection model), and protection against invasive challenge with 12 different serotypes of S. "
08/01/1998 - "b) Immunological study: detection of circulating antigen on the 3rd, 5th, 7th and 9th day p.i. The results showed that IL-2 was most effective when administered before and after infection in the form of significant reduction in parasitic count, least number of living tachyzoites, significant reduction in the death rate of infected mice and delayed appearance of circulating antigen with reduction in its level."
12/01/1992 - "Direct detection of respiratory syncytial (RS) virus antigen in nasopharyngeal secretions (NPS) provides the most rapid diagnostic test for RS infection, but more sensitive methods might be more beneficial in the study of virus shedding. "
11/01/2014 - "Immunoassays for parasitic antigens are not available for most parasitic infections and have not significantly improved the sensitivity of laboratory detection. "
01/01/2014 - "In this report, we show that CJ2-gD2 elicits a strong antibody response to various HSV-2 antigens and is highly effective in the prevention of primary and recurrent HSV-2 genital infection and disease in the immunized guinea pigs. "
12/01/1978 - "Eight of ten in the hepatitis B antigen-postive group cleared their antigen and had complete clinical recovery. "
07/01/2001 - "In adults at risk for a reduced response to hepatitis B vaccination [i.e., older adults (>/=40), the obese, males, and smokers], the triple antigen vaccine produced a significantly greater percentage of protected subjects (P < 0.001) and higher geometric mean titre (P < 0.001). "
07/01/2002 - "Sustained serological clearance of hepatitis B e antigen was associated with activation of CD4 positive HBV-specific T-cell reactivity and were of T-helper 1. Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored."
12/01/1993 - "Delayed clearance of hepatitis B e antigen occurred more frequently in nonresponders who had elevated pretreatment serum transaminase levels. "
12/01/1993 - "Twenty-eight (28%) nonresponders had sustained clearance of hepatitis B e antigen during follow-up. "
01/01/2009 - "It is likely that apart from differences in study methodologies, differences in exposure among study subjects within each study and brevity of antibody responses to malaria antigen are important sources of the variation in protective efficacy of anti-malaria immune responses mentioned above. "
01/01/2010 - "Cytotoxic T lymphocytes (CTL) directed against Plasmodium falciparum-derived antigens are shown to play an important role for the protection against malaria. "
11/01/2008 - "Cytotoxic T lymphocytes (CTL) directed against Plasmodium falciparum-derived antigens were shown to play an important role for the protection against malaria. "
01/01/2008 - "Antigen-specific antibody-mediated immune responses play an important role in natural protection against clinical malaria, but conflicting estimates of this association have emerged from immuno-epidemiological studies in different geographical settings. "
01/01/2006 - "Nevertheless, together the data have important implications for development of an effective malaria vaccine since the selection of appropriate Plasmodium antigens and/or adjuvants, targeting innate immune responses involving DCs, may provide optimal protection against malaria. "
|5.||Melanoma (Melanoma, Malignant)
05/01/1988 - "The results showed that 5-azadCyd was effective in inducing antigen expression in both systems whereas HU was effective (and equally so) only in the human melanoma cell line system. "
05/01/1987 - "The chimeric antibody, but not the mouse L6 antibody, is effective against a melanoma line expressing small amounts of the L6 antigen. "
08/01/1985 - "However, a melanoma cell line that expresses minimal levels of GD3 on 13% of the cells shows insignificant lysis by MB3.6 by either of these two mechanisms, suggesting that a threshold level of antigen expression may be required for effective in vitro cytolysis. "
05/01/2005 - "Although MVA-hTyr provides a safe and effective antigen-delivery system, it does not elicit a measurable immune response to its transgene product in patients with stage II melanoma after repeated combined intradermal and subcutaneous vaccination. "
08/01/2013 - "Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32% rejection of long-established immunogenic melanomas. "
|3.||DNA (Deoxyribonucleic Acid)
|4.||Hepatitis B e Antigens
|6.||Immunoglobulin G (IgG)
|7.||Hepatitis B Surface Antigens (HBsAg)
|2.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|5.||Heterologous Transplantation (Xenotransplantation)